Kit formulation of Bevacizumab, an anti-VEGF monoclonal antibody, and consequent labelling with Rhenium-188: initial in vitro and in vivo studies

被引：0
|
作者：
Bouziotis, P. [1 ]
Gourni, E. [1 ]
Xanthopoulos, S. [1 ]
Paravatou, M. [1 ]
Syrigos, K. [2 ]
Loudos, G. [3 ]
Archimandritis, S. C. [1 ]
Varvarigou, A. D. [1 ]
Harris, A. L. [4 ]
机构：
[1] NCSR Demokritos, Inst Radioisotopes & Radiodiagnost Prod, Athens, Greece
[2] Sotiria Gen Hosp, Dept Med 3, Med Oncol Unit, Athens, Greece
[3] Technol Educ Inst Athens, Dept Med Instruments Technol, Athens, Greece
[4] Univ Oxford, Inst Mol Med, Mol Oncol Lab, Oxford, England
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2008年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S320 / S321
页数：2
相关论文
共 48 条
  • [1] Thiol modification of bevacizumab, an anti-VEGF monoclonal antibody: labeling with Technetium-99m and initial in vitro and in vivo studies
    Bouziotis, P.
    Gourni, E.
    Harris, A. L.
    Loudos, G.
    Sakellios, N.
    Livaniou, E.
    Paravatou, M.
    Xanthopoulos, S.
    Archimandritis, S.
    Varvarigou, A. D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S260 - S260
  • [2] Conjugation, labelling and in vitro/in vivo assessment of an anti-VEGF monoclonal antibody labelled with niobium isotopes
    de la Fuente, A.
    Radchenko, V.
    Tsotakos, T.
    Tsoukalas, C.
    Paravatou-Petsotas, M.
    Harris, A. L.
    Koster, U.
    Roesch, F.
    Bouziotis, P.
    JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, 2018, 318 (03) : 1991 - 1997
  • [3] Conjugation, labelling and in vitro/in vivo assessment of an anti-VEGF monoclonal antibody labelled with niobium isotopes
    A. de la Fuente
    V. Radchenko
    T. Tsotakos
    C. Tsoukalas
    M. Paravatou-Petsotas
    A. L. Harris
    U. Köster
    F. Rösch
    P. Bouziotis
    Journal of Radioanalytical and Nuclear Chemistry, 2018, 318 : 1991 - 1997
  • [4] Bevacizumab: Anti-VEGF monoclonal antibody, avastin, rhumab-VEGF
    不详
    Drugs in R & D, 2002, 3 (1) : 28 - 30
  • [5] Pentavalent rhenium-188 dimercaptosuccinic acid: a new kit formulation and its initial evaluation in mice
    Pirmettis, I
    Limouris, GS
    Bouziotis, P
    Papadopoulos, M
    Knapp, FF
    Chiotellis, E
    RADIOCHIMICA ACTA, 2001, 89 (02) : 115 - 118
  • [6] Current clinical trials of the anti-VEGF monoclonal antibody bevacizumab
    Chen, HX
    Gore-Langton, RE
    Cheson, BD
    ONCOLOGY-NEW YORK, 2001, 15 (08): : 1017 - +
  • [7] Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro
    Wang Y.
    Fei D.
    Vanderlaan M.
    Song A.
    Angiogenesis, 2004, 7 (4) : 335 - 345
  • [8] Ambiguous effects of anti-VEGF monoclonal antibody (bevacizumab) for POEMS syndrome
    Sekiguchi, Yukari
    Misawa, Sonoko
    Shibuya, Kazumoto
    Nasu, Saiko
    Mitsuma, Satsuki
    Iwai, Yuta
    Beppu, Minako
    Sawai, Setsu
    Ito, Shoichi
    Hirano, Shigeki
    Nakaseko, Chiaki
    Kuwabara, Satoshi
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2013, 84 (12): : 1346 - 1348
  • [9] Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
    Ferrara, N
    Hillan, KJ
    Novotny, W
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 333 (02) : 328 - 335
  • [10] Scintigraphic imaging of VEGF-A expression with radiolabeled ANTI-VEGF monoclonal antibody (bevacizumab)
    Scheer, M.
    Stollman, T. H.
    Leenders, W. P. J.
    Verrijp, K.
    Soede, A. C.
    Oyen, W. J. G.
    Ruers, T. J. M.
    Boatman, O. C.
    ANNALS OF ONCOLOGY, 2008, 19 : I38 - I38
12345